| Original language | English (US) |
|---|---|
| Pages (from-to) | 2387-2388 |
| Number of pages | 2 |
| Journal | Journal of the American Society of Nephrology |
| Volume | 32 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2021 |
ASJC Scopus subject areas
- Nephrology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the American Society of Nephrology, Vol. 32, No. 9, 09.2021, p. 2387-2388.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Novel phenotypes for acute kidney transplant rejection using semi-supervised clustering
AU - Matas, Arthur J.
AU - Mannon, Roslyn B.
AU - Rush, David
AU - Helgeson, Erika
N1 - Funding Information: R.B. Mannon reports serving on the American Society of Nephrology (ASN) Grants Committee, as chair of the ASN Policy and Advocacy Committee, as the chair of the data safety monitoring board for the National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health, on the program committee for The Transplantation Society 2020 and 2022, as cochair of the Scientific Registry of Transplant Recipients Review Committee, and as chair of Women in Transplantation; receiving research funding from Astellas, CareDx, CSL Behring, Mallinckrodt, Quark Pharmaceuticals, and Transplant Genomics Inc.; receiving honoraria from CSL Behring, Hansa, Novartis, Sanofi, and Vitaeris; and serving on the steering committee for the Vitaeris VKTX01 IMAGINE Trial. A.J. Matas reports receiving research funding from Alexion, Astellas, Bristol Myers Squibb, CareDX, Shire, and Veloxis; receiving honoraria from Astellas, CareDX, CSL Behring, and Veloxis; serving as a scientific advisor for, or member of, CareDX, CSL Behring, and Jazz Pharma; and having consultancy agreements with Veloxis. D. Rush reports receiving research funding and honoraria from, serving as a scientific advisor for/member of, serving on a speakers bureau for, and having other interests/relationships (as a meeting steering committee member) in Astellas Canada Inc. The remaining author has nothing to disclose.
PY - 2021/9
Y1 - 2021/9
UR - http://www.scopus.com/inward/record.url?scp=85114362686&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114362686&partnerID=8YFLogxK
U2 - 10.1681/ASN.2021040572
DO - 10.1681/ASN.2021040572
M3 - Letter
C2 - 34403355
AN - SCOPUS:85114362686
SN - 1046-6673
VL - 32
SP - 2387
EP - 2388
JO - Journal of the American Society of Nephrology
JF - Journal of the American Society of Nephrology
IS - 9
ER -